According to Zacks, “Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros’ most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. “
Other equities analysts have also recently issued research reports about the company. Wedbush set a $19.00 target price on Symantec and gave the stock a hold rating in a report on Monday, July 15th. ValuEngine cut Yirendai from a sell rating to a strong sell rating in a report on Wednesday, June 26th. HC Wainwright set a $55.00 target price on Acer Therapeutics and gave the stock a buy rating in a report on Tuesday, May 28th. BidaskClub cut Vertex Pharmaceuticals from a buy rating to a hold rating in a report on Tuesday, July 9th. Finally, Cantor Fitzgerald restated a buy rating and set a $71.00 price objective on shares of ExlService in a report on Monday, May 6th. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the company. Omeros has an average rating of Hold and a consensus price target of $25.80.
Omeros (NASDAQ:OMER) last released its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.04). The business had revenue of $21.80 million during the quarter, compared to analyst estimates of $23.18 million. Omeros’s quarterly revenue was up 1271.1% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.62) EPS. As a group, equities research analysts expect that Omeros will post -1.68 earnings per share for the current fiscal year.
Institutional investors have recently bought and sold shares of the business. Miramar Capital LLC purchased a new stake in shares of Omeros in the fourth quarter worth about $192,000. Quad Cities Investment Group LLC boosted its stake in shares of Omeros by 28.2% in the first quarter. Quad Cities Investment Group LLC now owns 13,650 shares of the biopharmaceutical company’s stock worth $236,000 after buying an additional 3,000 shares during the last quarter. D. E. Shaw & Co. Inc. boosted its stake in shares of Omeros by 49.5% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 1,912,244 shares of the biopharmaceutical company’s stock worth $21,303,000 after buying an additional 632,840 shares during the last quarter. Legal & General Group Plc boosted its stake in shares of Omeros by 12.7% in the fourth quarter. Legal & General Group Plc now owns 8,370 shares of the biopharmaceutical company’s stock worth $93,000 after buying an additional 945 shares during the last quarter. Finally, Keeley Teton Advisors LLC boosted its stake in shares of Omeros by 32.3% in the first quarter. Keeley Teton Advisors LLC now owns 17,201 shares of the biopharmaceutical company’s stock worth $299,000 after buying an additional 4,200 shares during the last quarter. Institutional investors and hedge funds own 52.12% of the company’s stock.
Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.
Featured Article: How dollar cost averaging works
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.